TTOO Historical Financial Ratios
| TTOO Stock | USD 0.39 0.06 14.33% |
T2 Biosystms is promptly reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 0.0, Stock Based Compensation To Revenue of 0.57, Capex To Depreciation of 0.21 or Ev To Sales of 6.63 will help investors to properly organize and evaluate T2 Biosystms financial condition quickly.
TTOO |
About TTOO Financial Ratios Analysis
T2 BiosystmsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate T2 Biosystms investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on TTOO financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across T2 Biosystms history.
T2 Biosystms Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing T2 Biosystms stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on T2 Biosystms sales, a figure that is much harder to manipulate than other T2 Biosystms multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from T2 Biosystms' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.At this time, T2 Biosystms' Days Sales Outstanding is very stable compared to the past year. As of the 13th of December 2024, Days Of Inventory On Hand is likely to grow to 120.22, while Price To Sales Ratio is likely to drop 2.16.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 7.31 | 16.31 | 10.06 | 14.63 | Days Of Inventory On Hand | 68.92 | 75.09 | 114.49 | 120.22 |
T2 Biosystms fundamentals Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 6.39 | 8.3 | 2.92 | 0.32 | 2.28 | 2.16 | |
| Ptb Ratio | (1.57) | 17.24 | (6.35) | (0.18) | (0.58) | (0.56) | |
| Days Sales Outstanding | 123.71 | 102.65 | 66.79 | 35.4 | 72.06 | 131.22 | |
| Book Value Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
| Free Cash Flow Yield | (0.87) | (0.29) | (0.48) | (7.04) | (2.95) | (2.8) | |
| Operating Cash Flow Per Share | (5.0K) | (1.8K) | (1.2K) | (992.67) | (18.44) | (19.37) | |
| Stock Based Compensation To Revenue | 0.65 | 0.22 | 0.25 | 0.29 | 0.6 | 0.57 | |
| Capex To Depreciation | 0.24 | 0.21 | 0.25 | 0.18 | 0.15 | 0.22 | |
| Pb Ratio | (1.57) | 17.24 | (6.35) | (0.18) | (0.58) | (0.56) | |
| Ev To Sales | 10.44 | 10.45 | 4.17 | 2.52 | 6.98 | 6.63 | |
| Free Cash Flow Per Share | (5.1K) | (1.8K) | (1.2K) | (999.31) | (18.52) | (19.44) | |
| Roic | (6.26) | (0.81) | (1.34) | (5.12) | (3.34) | (3.51) | |
| Inventory Turnover | 4.66 | 5.85 | 5.3 | 4.86 | 3.19 | 3.03 | |
| Net Income Per Share | (6.9K) | (2.0K) | (1.7K) | (1.2K) | (19.19) | (20.15) | |
| Days Of Inventory On Hand | 78.37 | 62.37 | 68.92 | 75.09 | 114.49 | 120.22 | |
| Payables Turnover | 4.47 | 10.34 | 7.31 | 16.31 | 10.06 | 14.63 | |
| Research And Ddevelopement To Revenue | 1.96 | 0.93 | 0.78 | 1.16 | 1.97 | 1.87 | |
| Capex To Revenue | 0.0913 | 0.0443 | 0.0164 | 0.0152 | 0.0267 | 0.0254 | |
| Cash Per Share | 1.2K | 1.7K | 1.0K | 202.52 | 6.01 | 5.71 | |
| Pocfratio | (1.17) | (3.48) | (2.11) | (0.14) | (0.34) | (0.36) | |
| Interest Coverage | (7.08) | (7.51) | (6.52) | (9.12) | (9.3) | (9.76) | |
| Capex To Operating Cash Flow | (0.0168) | (0.0186) | (0.0118) | (0.006696) | (0.003989) | (0.004188) | |
| Pfcf Ratio | (1.15) | (3.42) | (2.08) | (0.14) | (0.34) | (0.36) | |
| Days Payables Outstanding | 81.72 | 35.3 | 49.93 | 22.38 | 36.28 | 57.38 | |
| Roe | 1.86 | (5.64) | 4.15 | 1.59 | 1.79 | 1.88 | |
| Ev To Operating Cash Flow | (1.92) | (4.38) | (3.01) | (1.11) | (1.04) | (1.1) | |
| Pe Ratio | (0.84) | (3.06) | (1.53) | (0.11) | (0.33) | (0.34) | |
| Return On Tangible Assets | (2.22) | (0.62) | (0.88) | (1.84) | (1.44) | (1.51) | |
| Ev To Free Cash Flow | (1.89) | (4.3) | (2.97) | (1.1) | (1.04) | (1.09) | |
| Earnings Yield | (1.19) | (0.33) | (0.65) | (8.75) | (3.06) | (2.9) | |
| Net Debt To E B I T D A | (0.7) | (1.01) | (0.85) | (0.89) | (0.77) | (0.73) | |
| Current Ratio | 0.31 | 5.47 | 3.8 | 1.85 | 0.45 | 0.43 | |
| Tangible Book Value Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
| Receivables Turnover | 2.95 | 3.56 | 5.47 | 10.31 | 5.07 | 5.11 | |
| Graham Number | 24.1K | 4.1K | 3.9K | 4.7K | 68.1 | 64.69 | |
| Shareholders Equity Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
| Debt To Equity | (1.26) | 5.18 | (3.7) | (1.28) | (1.53) | (1.45) | |
| Capex Per Share | 83.61 | 33.13 | 14.48 | 6.65 | 0.0736 | 0.0699 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.